布美他尼：强效新型“袢”利尿剂。
Bumetanide: potent new "loop" diuretic.
作者信息
Asbury M J, Gatenby P B, O'Sullivan S, Bourke E
出版信息
Br Med J. 1972 Jan 22;1(5794):211-3. doi: 10.1136/bmj.1.5794.211.
Abstract
Bumetanide, a pharmacologically new diuretic, was evaluated in 27 subjects. Its onset of action was within 30 minutes with a peak at 90 minutes and a total duration of action of about 270 minutes. In a controlled study in oedematous patients it was equipotent with frusemide at one-fortieth the molar dosage and did not differ from frusemide with regard to its pattern of electrolyte excretion. On continuous oral administration for eight days it produced effective diuresis with minimal alteration in biochemical and haematological status. The only adverse effect was gastric discomfort in one patient.
摘要
布美他尼是一种药理学上的新型利尿剂，对27名受试者进行了评估。其起效时间在30分钟内，90分钟时达到峰值，总作用持续时间约为270分钟。在一项针对水肿患者的对照研究中，其摩尔剂量为速尿的四十分之一时与速尿等效，且在电解质排泄模式方面与速尿无差异。连续口服八天可产生有效的利尿作用，对生化和血液学状态的影响最小。唯一的不良反应是一名患者出现胃部不适。
相似文献
1
Bumetanide: potent new "loop" diuretic.布美他尼：强效新型“袢”利尿剂。
Br Med J. 1972 Jan 22;1(5794):211-3. doi: 10.1136/bmj.1.5794.211.
2
Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.布美他尼，一种新型强效利尿剂。充血性心力衰竭的临床评估。
Acta Med Scand. 1973 Jan-Feb;193(1-2):119-31.
3
A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states.布美他尼与呋塞米治疗充血性心力衰竭及其他水肿状态的比较随机双盲临床试验。
Int J Clin Pharmacol Ther Toxicol. 1984 Sep;22(9):473-8.
4
5
Xipamid, a potent new diuretic.
Curr Med Res Opin. 1975;3(3):121-5. doi: 10.1185/03007997509113658.
6
Clinical trial of mefruside, a new diuretic.新型利尿剂美夫西特的临床试验
Br Med J. 1971 Dec 25;4(5790):786-8. doi: 10.1136/bmj.4.5790.786.
7
Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide.利尿剂布美他尼的肾脏作用、治疗用途及药代动力学
Clin Pharmacol Ther. 1974 Feb;15(2):141-55. doi: 10.1002/cpt1974152141.
8
Bumetanide, a new diuretic.布美他尼，一种新型利尿剂。
Int Urol Nephrol. 1974;6(1):35-42. doi: 10.1007/BF02086910.
9
Clinical trial of a new diuretic, bumetanide, in seriously ill patients.新型利尿剂布美他尼用于重症患者的临床试验。
Ann Clin Res. 1974 Oct;6(5):272-8.
引用本文的文献
1
Diuretics: a review of the pharmacology and effects on glucose homeostasis.利尿剂：药理学及其对葡萄糖稳态影响的综述
Front Pharmacol. 2025 Mar 28;16:1513125. doi: 10.3389/fphar.2025.1513125. eCollection 2025.
2
The biogenesis of potassium transporters: implications of disease-associated mutations.钾离子转运体的生物发生：疾病相关突变的影响
Crit Rev Biochem Mol Biol. 2024 Jun-Aug;59(3-4):154-198. doi: 10.1080/10409238.2024.2369986. Epub 2024 Jul 1.
3
The role of family of cation-chloride cotransporters and drug discovery methodologies.阳离子-氯离子共转运体家族的作用及药物发现方法
J Pharm Anal. 2023 Dec;13(12):1471-1495. doi: 10.1016/j.jpha.2023.09.002. Epub 2023 Sep 9.
4
Structural Pharmacology of Cation-Chloride Cotransporters.阳离子-氯离子共转运体的结构药理学
Membranes (Basel). 2022 Nov 29;12(12):1206. doi: 10.3390/membranes12121206.
5
A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders.布美他尼对自闭症谱系障碍的缓解的整体观。
Cells. 2022 Aug 4;11(15):2419. doi: 10.3390/cells11152419.
6
Advances in the development of novel compounds targeting cation-chloride cotransporter physiology.新型化合物靶向阳离子-氯离子共转运体生理学的研究进展。
Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C324-C340. doi: 10.1152/ajpcell.00566.2020. Epub 2020 Dec 23.
7
NKCC1: Newly Found as a Human Disease-Causing Ion Transporter.NKCC1：新发现的人类疾病致病离子转运体。
Function (Oxf). 2021;2(1):zqaa028. doi: 10.1093/function/zqaa028. Epub 2020 Nov 3.
8
Off-Label Use of Bumetanide for Brain Disorders: An Overview.布美他尼在脑部疾病中的超说明书用药概述
Front Neurosci. 2019 Apr 24;13:310. doi: 10.3389/fnins.2019.00310. eCollection 2019.
9
Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures.奈莫试验失败：布美他尼是治疗多种脑部疾病的有前景药物，但对新生儿癫痫无效。
Front Cell Neurosci. 2016 Apr 14;10:90. doi: 10.3389/fncel.2016.00090. eCollection 2016.
10
Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.在结肠癌模型中，使用可生物降解的大分子造影剂通过动态对比增强磁共振成像揭示布美他尼的抗血管生成作用。
Pharm Res. 2015 Sep;32(9):3029-43. doi: 10.1007/s11095-015-1684-4. Epub 2015 Apr 4.
本文引用的文献
1
SIMPLE AUTOMATED METHOD FOR URINARY CREATININE ESTIMATION.尿肌酐估算的简易自动化方法。
J Clin Pathol. 1965 May;18(3):377-8. doi: 10.1136/jcp.18.3.377.
2
STUDIES ON ETHACRYNIC ACID IN PATIENTS WITH REFRACTORY EDEMA.难治性水肿患者的依他尼酸研究。
Ann Intern Med. 1965 Jan;62:15-29. doi: 10.7326/0003-4819-62-1-15.
3
CLINICAL TRIAL OF A NEW DIURETIC: ETHACRYNIC ACID.一种新型利尿剂——依他尼酸的临床试验
J Ir Med Assoc. 1965 Jan;56:1-8.
4
Influence of probenecid and alterations in acid-base balance of the saluretic activity of furosemide.丙磺舒及酸碱平衡改变对呋塞米利尿活性的影响。
J Pharmacol Exp Ther. 1965 Sep;149(3):404-8.
5
An inhibitory effect of furosemide on sodium reabsorption by the proximal tubule of the rat nephron.速尿对大鼠肾单位近端小管钠重吸收的抑制作用。
J Clin Invest. 1969 Feb;48(2):290-300. doi: 10.1172/JCI105985.
6
The relationship between glomerular filtration rate and sodium reabsorption by the proximal tubule of the rat nephron.大鼠肾单位近端小管的肾小球滤过率与钠重吸收之间的关系。
J Clin Invest. 1968 Jun;47(6):1358-74. doi: 10.1172/JCI105828.
7
Studies with uraemic serum on the renal transport of hippurates and tetraethylammonium in the rabbit and rat: effects of oral neomycin.
Clin Sci. 1970 Jan;38(1):41-8. doi: 10.1042/cs0380041.
8
Physiologic and clincical observations on furosemide and ethacrynic acid.
Ann N Y Acad Sci. 1966 Nov 22;139(2):453-65. doi: 10.1111/j.1749-6632.1966.tb41219.x.
9
Indications and contraindications for diuretic therapy.利尿疗法的适应证和禁忌证。
Ann N Y Acad Sci. 1966 Nov 22;139(2):481-96. doi: 10.1111/j.1749-6632.1966.tb41222.x.
10
Aminobenzoic acid diuretics. 2. 4-Substituted-3-amino-5-sulfamylbenzoic acid derivatives.氨基苯甲酸类利尿剂。2. 4-取代-3-氨基-5-氨磺酰苯甲酸衍生物。
J Med Chem. 1971 May;14(5):432-9. doi: 10.1021/jm00287a014.
Zotero 插件